GSK plc (NYSE:GSK) Shares Sold by Ritholtz Wealth Management

Ritholtz Wealth Management decreased its position in GSK plc (NYSE:GSK) by 8.4% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 71,933 shares of the pharmaceutical company’s stock after selling 6,607 shares during the quarter. Ritholtz Wealth Management’s holdings in GSK were worth $2,433,000 at the end of the most recent reporting period.

Other large investors have also bought and sold shares of the company. FMR LLC raised its holdings in shares of GSK by 8.3% in the 3rd quarter. FMR LLC now owns 29,008,928 shares of the pharmaceutical company’s stock worth $1,185,885,000 after purchasing an additional 2,224,345 shares in the last quarter. Healthcare of Ontario Pension Plan Trust Fund acquired a new position in GSK in the second quarter worth approximately $52,487,000. Fisher Asset Management LLC increased its holdings in shares of GSK by 4.9% in the third quarter. Fisher Asset Management LLC now owns 18,576,930 shares of the pharmaceutical company’s stock valued at $759,425,000 after buying an additional 870,449 shares in the last quarter. Hotchkis & Wiley Capital Management LLC lifted its position in shares of GSK by 30.8% during the 3rd quarter. Hotchkis & Wiley Capital Management LLC now owns 3,542,143 shares of the pharmaceutical company’s stock valued at $144,803,000 after acquiring an additional 833,080 shares during the last quarter. Finally, Dimensional Fund Advisors LP lifted its position in shares of GSK by 33.8% during the 2nd quarter. Dimensional Fund Advisors LP now owns 2,256,320 shares of the pharmaceutical company’s stock valued at $86,875,000 after acquiring an additional 569,614 shares during the last quarter. Institutional investors own 15.74% of the company’s stock.

GSK Trading Up 0.0 %

Shares of NYSE GSK opened at $33.46 on Friday. The company has a current ratio of 0.81, a quick ratio of 0.53 and a debt-to-equity ratio of 0.98. GSK plc has a one year low of $31.72 and a one year high of $45.92. The business has a 50-day moving average price of $34.08 and a two-hundred day moving average price of $38.01. The firm has a market capitalization of $69.34 billion, a PE ratio of 21.72, a PEG ratio of 1.44 and a beta of 0.63.

GSK Increases Dividend

The business also recently disclosed a quarterly dividend, which was paid on Thursday, January 9th. Investors of record on Friday, November 15th were given a dividend of $0.3928 per share. The ex-dividend date was Friday, November 15th. This is an increase from GSK’s previous quarterly dividend of $0.38. This represents a $1.57 dividend on an annualized basis and a yield of 4.70%. GSK’s payout ratio is presently 96.10%.

Wall Street Analyst Weigh In

A number of equities research analysts have recently issued reports on the company. Deutsche Bank Aktiengesellschaft lowered GSK from a “buy” rating to a “hold” rating in a research report on Friday, November 15th. Guggenheim downgraded GSK from a “buy” rating to a “neutral” rating in a report on Thursday, October 31st. Jefferies Financial Group lowered shares of GSK from a “buy” rating to a “hold” rating and reduced their price objective for the company from $53.00 to $39.50 in a research note on Tuesday, November 12th. Finally, StockNews.com raised shares of GSK from a “buy” rating to a “strong-buy” rating in a research report on Monday, January 13th. Seven equities research analysts have rated the stock with a hold rating and four have given a strong buy rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $43.25.

GSK Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.